Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD

Next Previous
X
Search
Trial Profile

A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensifentrine (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Verona Pharma

    • Most Recent Events

    • 19 May 2021 Results from two, Phase 2b studies NCT03443414 (n=403) and NCT03937479 (n=413) assessing the efficacy and safety of multiple doses of nebulized ensifentrine in patients with moderate-severe chronic obstructive pulmonary disease, presented at the 117th International Conference of the American Thoracic Society.
    • 04 May 2021 According to a Verona Pharma media release, data from the study will be presented at the American Thoracic Society International Conference (ATS) 2021. The abstracts are published on the ATS website.
    • 04 May 2021 According to a Verona Pharma media release, data from the study has been published in the peer reviewed publication, American Journal of Respiratory and Critical Care Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top